01 / DESIGN
What was studied?
Participants first received semaglutide during a 20-week run-in. Those reaching the study maintenance exposure were then randomized to continue or switch to placebo for a further 48 weeks, with lifestyle intervention in both groups.
02 / FINDINGS
What did the researchers report?
Continued treatment led to further average weight loss, while the group switched to placebo regained weight over the randomized phase. The comparison starts after the run-in, not at the original untreated baseline.
03 / LIMITS
How should it be interpreted?
Randomized participants were selected by completing the initial phase, so results do not describe every person who starts treatment. This design is distinct from the STEP 1 post-treatment extension already in the library. Neither establishes a permanent effect after withdrawal or catalog-material equivalence.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.